AP NEWS
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.
PRESS RELEASE from provider: Business Wire
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation.

Myoscience Announces Data Demonstrating iovera Therapy is an Effective Alternative to Opioids for Pain Relief Following Knee Replacement Surgery

March 12, 2019

FREMONT, Calif. & LAS VEGAS--(BUSINESS WIRE)--Mar 12, 2019--Myoscience, Inc., a medical device company dedicated to relieving pain through targeted therapies, today announced clinical trial results demonstrating that iovera° therapy significantly reduced the use of opioids following total knee arthroplasty (TKA) surgery (primary endpoint) and significantly reduced pain in a prospective, randomized study. Preliminary results will be presented tomorrow in the Innovation Theater at the 2019 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in Las Vegas by lead investigator William Mihalko, M.D., Ph.D., orthopedic surgeon at Campbell Clinic Orthopaedics in Memphis, Tenn.

Myoscience’s FDA-cleared platform technology, the iovera° system, uses cryoneurolysis to freeze nerves in the knee to deliver fast and immediate opioid-free pain relief with results that are sustained for up to 90 days. 1 During the simple outpatient procedure, iovera° safely and effectively allows patients with knee pain to leave their physician’s office experiencing less pain than they had when they walked in.

“While knee replacement surgery is an effective option for relieving pain and restoring function for patients, concern has shifted to addressing how outcomes are negatively affected by the prolonged use of opioids,” said Dr. Mihalko. “Cryoneurolysis with the iovera° system has made a measurable impact on pain relief, reduced patients’ use of opioids after surgery and improved overall knee function. I am seeing my patients recover more quickly, with less pain. We are confident the progress demonstrated by the positive preliminary data presented today is a strong indication for the final results of this clinical trial.”

Presentation time and location:

  • Cryoanalgesia: A Path to an Opioid-Free TKA, Pre-op Through Rehab
    Presented by lead author William Mihalko, M.D., Ph.D.
    Wednesday, March 13, 2:15 p.m. PT
    Innovation Theater, Booth 3032, Hall B

About the Campbell Clinic Orthopaedics study:

Patients scheduled to undergo a primary TKA (n = 125) were randomized 1:1 to a control group or a cryoneurolysis treatment group. Both groups followed the same pre-operative, intra-operative, and post-operative pain management protocols, except that the treatment group had the iovera° therapy administered to their superficial genicular nerves three to seven days before surgery. All patients were prescribed 40 opioid pills at discharge, and pills were counted at 72 hours and at two, six, and 12 weeks postoperatively.

The iovera° system met preliminary primary and secondary endpoints, including:

  • Daily morphine equivalent (DME), (primary endpoint, a measure taking of prescribed opioids based on pill count). DME was significantly lower at 72 hours (12.1 mg vs. 17.8 mg, p=0.014), six weeks (4.5 mg vs. 6.3 mg, p=0.025) and 12 weeks (2.3 mg vs 3.5 mg p=0.008) with an overall 35 percent reduction in the DMEs across the 12-week postoperative period in the iovera° treatment group.
  • Opioid use. Patients who had iovera° therapy were far less likely to take opioids six weeks after surgery. The number of patients taking opioids six weeks after TKA in the control group was three times the number of patients taking opioids in the cryoneurolysis treatment group.
  • Pain score. Patients in the iovera° treatment group demonstrated a significant reduction in pain scores from the baseline at 72 hours (0.59 vs. -0.60, p=0.021) and at 12 weeks (4.6 vs. 3.5, p=0.014).

“These data mark important progress in establishing iovera° therapy as a clinically validated alternative to opioids for patients recovering from total knee replacement,” said Timothy I. Still, president and CEO of Myoscience. “This trial represents our commitment to developing innovative technologies that offer a safe and reliable option for people suffering from chronic knee pain. We are grateful to Campbell Clinic Orthopaedics for leading this effort and making this trial possible.”

About Campbell Clinic and The Campbell Foundation

Founded in 1909 in Memphis, Campbell Clinic serves as a national leader in orthopaedics and sports medicine. Today, the organization operates five full-service outpatient clinics and two ambulatory surgery centers across the Mid-South. The Campbell Foundation, founded in 1946, is a scientific and charitable trust affiliated with Campbell Clinic Orthopaedics. The Foundation is committed to advancing surgeon education, orthopaedic research and community healthcare. To learn more about Campbell Clinic, visit www.campbellclinic.com. For more information on The Campbell Foundation, visit www.campbell-foundation.org.

About Myoscience, Inc.

Myoscience is a privately held medical device company committed to developing targeted peripheral nerve therapies to relieve acute (perioperative) and chronic pain in the body. Its platform technology, the iovera° system, freezes peripheral nerves through cryoneurolysis, delivering immediate and long-lasting opioid-free pain relief. For more information, please visit http://www.iovera.com. Stay updated with the company on Twitter at @iovera and on LinkedIn at myoscience.

1 Radnovich, R. et al. “Cryoneurolysis to treat the pain and symptoms of knee osteoarthritis: a multicenter, randomized, double-blind, sham-controlled trial.” Osteoarthritis and Cartilage (2017) p1-10.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190312005286/en/

CONTACT: Jana Chow

Health+Commerce

925-324-9846

jana@healthandcommerce.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEVADA

INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS MEDICAL DEVICES PHYSICAL THERAPY

SOURCE: Myoscience, Inc.

Copyright Business Wire 2019.

PUB: 03/12/2019 03:01 AM/DISC: 03/12/2019 03:01 AM

http://www.businesswire.com/news/home/20190312005286/en